Analyst Price Target is $15.50
▲ +493.87% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Biofrontera in the last 3 months. The average price target is $15.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 493.87% upside from the last price of $2.61.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Biofrontera.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Read More